Serina Therapeutics Announces Follow-on Agreement with AstraZeneca for Development of a Proprietary POZ-therapeutic

Huntsville, AL, June 2, 2015

Serina Therapeutics, Inc., a pharmaceutical research and development company that has developed a proprietary, patented polymer technology for drug development, announced today that the company has entered into a follow-on agreement with AstraZeneca for development of a POZ-therapeutic. The nature of the POZ-therapeutic and the financial terms of the agreement were not disclosed.

About Serina

Serina Therapeutics is a privately held pharmaceutical company located at the Hudson-Alpha Institute for Biotechnology in Huntsville, AL that develops novel polymer therapeutics based on its proprietary polyoxazoline (POZ) technology platforms. The founders and managers of Serina were formerly the key principals of Shearwater Polymers, a company that enabled twelve approved polyethylene glycol (PEG) products for various pharmaceutical partners. We believe our POZ technology provides strong differential characteristics that may demonstrate improved clinical benefits versus other polymer-based technologies. Besides developing its own pipeline of pharmaceutical products for Parkinson’s disease and cancer, Serina is also partnering its technology with pharmaceutical companies to develop high value products addressing unmet medical needs.

Serina’s pipeline programs are aimed primarily at oncology indications that address significant unmet medical needs. Polymers of POZ can be targeted to specific receptors on the surface of cancer cells using either small molecules or antibodies (POZ polymer ADCs), and this approach may provide a much wider therapeutic index when employing very potent toxins attached to the polymer.

For more information on Serina Therapeutics, please visit http://www.serinatherapeutics.com